Eli Lilly & Co. (LLY) delivered mixed results in FY2026 on revenue of $40.4B versus the $40.7B estimate (-5.0% YoY) and EPS of $3.71. Below is the full Eli Lilly & Co. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Eli Lilly & Co. (LLY) Earnings Analysis — key stats
Latest reported quarter
FY2026
Earnings verdict
Mixed
Revenue
$40.4B (vs $40.7B est · -0.7% surprise · -5.0% YoY)
EPS
$3.71 (vs $3.40 est · +9.1% surprise · -7.5% YoY)
Share price
$533.46 (+2.7%)
Market cap
$1.35T
What you'll find
Next Eli Lilly & Co. (LLY) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Eli Lilly & Co. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Eli Lilly & Co. (LLY)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Eli Lilly & Co.'s next earnings date?
Magnisto tracks Eli Lilly & Co.'s (LLY) earnings schedule and shows the confirmed next earnings date, the options-implied expected move and the estimates analysts are modeling into the print.
Did Eli Lilly & Co. (LLY) beat or miss earnings?
In FY2026, Eli Lilly & Co. (LLY) posted mixed results — revenue of $40.4B versus the $40.7B estimate (-0.7% surprise) and EPS of $3.71 versus $3.40 expected (+9.1% surprise). Magnisto decodes every Eli Lilly & Co. (LLY) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Eli Lilly & Co. (LLY) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Eli Lilly & Co. (LLY), anchored to the current $533.46 share price, so you can weigh the bull, base and bear cases for Eli Lilly & Co. side by side.
Is Eli Lilly & Co. (LLY) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Eli Lilly & Co. fits your own thesis and risk profile. This is research, not investment advice.